A previous retrospective study in patients with NSCLC with PD-L1–negative or PD-L1–low expression reported that ICI combination chemotherapy significantly prolonged OS, whereas another report indicated poor efficacy of ICI combination chemotherapy in older patients with low PD-L1 expression (13, 14). The gene discussed is CD274; the disease is non-small cell lung carcinoma.